Award
National Institute of Allergy and Infectious Diseases 1R01AI187899-01A1
Optimizing lipid RVn monophosphate prodrugs to maximize RVn-triphosphate delivery
Recipient
University of California, San Diego
Award Amount
$3,082,513.00
Ceiling
$3,082,513.00
Awarded
July 18, 2025
Identifier
1R01AI187899-01A1
This NIH-funded project focuses on developing improved oral antiviral drugs by optimizing lipid prodrug delivery of remdesivir nucleoside monophosphate to enhance efficacy against RNA viruses, including respiratory viruses.
Description
The project aims to optimize an innovative lipid prodrug delivery strategy for remdesivir nucleoside monophosphate (RVn-MP) and additional broad-spectrum nucleoside antivirals to achieve excellent oral bioavailability, efficient intracellular activation across tissue types, and bypass of liver metabolism to enhance tissue delivery. The goal is to identify scaffold modifications that maximize antiviral activity and tissue delivery, evaluate new compounds in vitro and in vivo, and develop broad-spectrum oral antivirals for RNA viruses.